US Patent

US8367734 — Stable epinephrine suspension formulation with high inhalation delivery efficiency

Formulation · Assigned to Amphastar Pharmaceuticals Inc · Expires 2026-01-26 · 0y expired

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a stable suspension aerosol formulation of epinephrine suitable for inhalation administration.

USPTO Abstract

A stable suspension aerosol formulation of epinephrine is suitable for administration through inhalation comprising a therapeutically effective amount of epinephrine, hydrofluorocarbon propellant, co-solvent, surfactant, and antioxidant. The suspension aerosol formulation further comprises [pre-] pre-micronized epinephrine suspended in an alcohol/surfactant solution with hydrofluoroalkane propellant. The suspension formulation provides a highly efficient delivery of drug microparticles into the respirable region of patients' lungs and has the following advantages: lower dosage requirement, minimum alcohol content, with less impurities generated during storage, improved efficacy and safety, and exhibits no ozone depleting potential compared to a formulation containing chlorofluorocarbon.

Drugs covered by this patent

Patent Metadata

Patent number
US8367734
Jurisdiction
US
Classification
Formulation
Expires
2026-01-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Amphastar Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.